Insider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells $34,885.71 in Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 1,311 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $34,885.71. Following the completion of the sale, the senior vice president now directly owns 115,633 shares in the company, valued at approximately $3,076,994.13. This represents a 1.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The shares were sold at an average price of $20.93, for a total transaction of $532,605.71.

Phreesia Stock Performance

Shares of PHR opened at $26.75 on Friday. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $29.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. The stock’s fifty day moving average price is $22.87 and its two-hundred day moving average price is $22.62. The firm has a market cap of $1.55 billion, a PE ratio of -18.20 and a beta of 0.94.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.58) EPS. On average, equities research analysts forecast that Phreesia, Inc. will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its holdings in Phreesia by 8.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 214,430 shares of the company’s stock valued at $4,546,000 after buying an additional 16,614 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Phreesia by 1.0% in the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock valued at $1,741,000 after acquiring an additional 853 shares during the period. Hsbc Holdings PLC purchased a new position in Phreesia during the second quarter valued at approximately $301,000. Sei Investments Co. increased its holdings in Phreesia by 135.3% during the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after acquiring an additional 95,058 shares during the period. Finally, Ensign Peak Advisors Inc lifted its stake in Phreesia by 3.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after purchasing an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

PHR has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird dropped their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. KeyCorp increased their price target on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $24.00 to $32.00 in a report on Wednesday. Finally, Citigroup lifted their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.